Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00451984
NCT00451984UnknownPhase 3

Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2

Aalborg University Hospital2 sites in 1 country80 target enrollmentStarted: March 1, 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 3
Enrollment
80
Locations
2
Primary Endpoint
Antibody response to hepatitis A and hepatitis B
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Single Group
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Adults with stable antiretroviral therapy and negative for hepatitis A or B

Exclusion Criteria

  • •Prior hepatitis A or B

Outcomes

Primary Outcomes

Antibody response to hepatitis A and hepatitis B

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 3
Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected PatientsHIV Infection
NCT00190242Assistance Publique - Hôpitaux de Paris99
Active, not recruiting
Phase 1
Hepatitis vaccination til patienter med HIV infektion. Betydning af adjuverende interleukin-2Patienter med Hiv infektion har øget risiko for hepatitis A og hepatitis B. Sundhedsmyndigheder anbefaler vaccination. Effekt er imidlertid mindre end for raske personer. Forsøget tester om adjuverende interleukin-2 øger effekt.
EUCTR2005-002171-33-DKAalborg Sygehus Syd50
Active, not recruiting
Phase 4
Understanding Poor Vaccine Responses to Hepatitis B VaccinationVaccine Reaction
NCT04674462NYU Langone Health101
Unknown
Phase 4
Immunogenicity and Persistence of Hepatitis B Vaccination in HIV-Infected PatientsHepatitis B Vaccine
NCT03962803Shanxi Medical University300
Unknown
Not Applicable
A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment OutcomesIntestinal HelminthiasisHuman Immunodeficiency Virus I InfectionHematologic DiseasesOpportunistic InfectionsIntestinal SchistosomiasisAnemia
NCT01541631Catholic University of Health and Allied Sciences2,000